A study of M254 (Hyper-sialylated IVIg)
Phase of Trial: Phase I
Latest Information Update: 08 May 2018
At a glance
- Drugs M-254 (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions
- 08 May 2018 According to a Momenta Pharmaceuticals media release, the company is planning to commence this trial in the second half of 2018.
- 21 Feb 2018 According to a Momenta Pharmaceuticals media release, company is planning to initiate this trial in first half of 2018.
- 08 May 2017 New trial record